期刊
JOURNAL OF CYSTIC FIBROSIS
卷 16, 期 2, 页码 246-249出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcf.2016.11.001
关键词
-
资金
- Vertex Pharmaceuticals Incorporated
In an open-label, single-center phase 1 pharmacokinetic study in healthy subjects who received lumacaftor (LUM) in combination with ivacaftor (IVA), review of spirometry data showed a transient decline in percent predicted forced expiratory volume in 1 s (ppFEV(1)) within 4 h of drug administration. An additional cohort of healthy subjects with normal baseline ppFEV(1) values was studied to evaluate the ppFEV(1) response to LUM/IVA administration and assess the effect of long-acting bronchodilators (LABDs) and short-acting bronchodilators (SABDs) on ppFEV(1) response. The ppFEV(1) decline observed at 4 h was attenuated following administration of an LABD and reversed following administration of an SABD. Concomitant administration of LUM/IVA with bronchodilators was well tolerated. These data show that a transient decline in ppFEV(1) was observed in healthy subjects following administration of LUM/IVA combination therapy, which can be ameliorated with LABDs or SABDs. (C) 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据